Treatment of neurodegenerative diseases
Alzprotect is a French biotechnology company that develops molecules for the treatment of neurodegenerative diseases.
- Alzprotect currently has the world’s most advanced clinical development program for the treatment of PSP.
- Progressive Supranuclear Palsy (PSP) affects over 25,000 US citizens each year. The American market therefore represents the main world market for the treatment of PSP.
- Phase 2a for the treatment of PSP went well and was completed on July 17, 2022.
Lille, France – June 1st 2022 – Alzprotect, a French biopharmaceutical company involved in the development of new therapeutic solutions in the neurodegenerative diseases ...Read more...
Lille (France), November 23rd, 2020 ALZPROTECT, a biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases announces today that the United ...Read more...
With an ageing population in industrialised countries, the number of people affected by Alzheimer's disease is increasing dramatically. According to the ...Read more...
error: Content is protected !!